Science Dialogue January 30 (Tues), 2007 at Niigata Prefectural Takada High School

Size: px
Start display at page:

Download "Science Dialogue January 30 (Tues), 2007 at Niigata Prefectural Takada High School"

Transcription

1 Science Dialogue January 30 (Tues), 2007 at Niigata Prefectural Takada High School Unique features of chronic myeloid leukemia in southern Vietnam (defoliants sprayed area) -- association with problem of dioxin pollution-- International Medical Center of Japan Research Institute, Division of Ultrafine Structure Phan Thi Xinh, Yuko Sato 1

2 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin pollution in Vietnam by Kanazawa University and our direction of further study 6. Dioxin pollution in Japan: in the past and the present 2

3 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin polution in Vietnam by Kanazawa University and our direction of further study 6. Dioxin pollution in Japan: in the past and the present 3

4 Dioxins--- 3 group (Toxicity is different) 1. polychlorinated dibenzo p-dioxins: PCDDs 7 kinds (75) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): Difficult to be decomposed in the environment, most toxic even a small amount 10 kinds (135) 2. polychlorinated dibenzofurans: PCDFs 3. coplanar polychlorinated biphenyls: Co-PCBs 12 kinds (29) 4

5 Physiologic effects of dioxins--1 Strong carcinogenic and teratogenic substance (most toxic among artificial substances) Generated in burning at around 300 (discomposed in burning at more than 800 ) Dioxins derived from agricultural chemicals: 4 times higher than that derived from waste incinerators Sensitivity of acute toxicity: exceedingly different among animals hamster (most sensitive) 1/800 of LD 50 guinea pig (most resistant) Human beings : resistant to dioxins however, to determine toxicity level (acute and chronic) is difficult Soluble in oil concentrated in human body through food chain a half life 7-12 years

6 Physiologic effects of dioxins--2 chronic toxicity High frequency of Reproduction abnormalities (infertility, abortion, stillbirth, congenital abnormalities, endometritis) Estrogen-like substance environmental hormone Most dangerous chemical in the environment 6

7 How to evaluate dioxins toxicity the toxicity of 2,3,7,8-TCDD = 1, and determine TEF toxic equivalency factor on each compound each compound x TEF TEQ (toxicity equivalency quantity We adapted WHO-TEF from 1997 in Japan. PCDDs TEF 2,3,7,8-TCDD 1 1,2,3,7,8-PeCDD 1 1,2,3,4,7,8-HxCDD 0.1 1,2,3,6,7,8-HxCDD 0.1 1,2,3,6,7,8-HxCDD 0.1 1,2,3,4,6,7,8-HpCDD 0.01 PCDFs TEF 2,3,7,8-TCDF 0.1 1,2,3,7,8-PeCDF ,3,4,7,8-PeCDF 0.5 1,2,3,4,7,8-HxCDF 0.1 1,2,3,6,7,8-HxCDF 0.1 1,2,3,7,8,9-HxCDF 0.1 7

8 Agent orange sprayed area in southern Vietnam Duration: Sprayed area >21,000 km 2 especially around US air-force base Sprayed volume 72x10 6 L (as dioxins:170 kg) Lat. 17 N 55% of mangrove area was destroyed (reported by VN 1080 division) 8

9 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin pollution in Vietnam by Kanazawa University and our direction of further study 6. Dioxin pollution in Japan: in the past and the present 9

10 Chronic Myeloid Leukemia: CML Increased WBC sometimes > 300,000/cmm 3 (WBC: 3,500-8,500/cmm 3 : normal value) WBC>50,000/cmm 3 splenomegaly WBC>70,000/cmm 3 general fatigue, weight loss, easy fatiguability, fever, abdominal fullness due to hepato-splenomegaly CML will be found at the health examination in Japan 10

11 Description of CML in old history In old Greek era: there is already a description of CML 1827 By Verbow the first accurate description of leukemic patients 63-year-old male: abdominal enlargement, fever, fatigue at autopsy, blood looked like wine-like pus 1835 by Donne 44-year-old male: splenomegaly, more than a half of blood was occupied with white blood cells Leukemia is a suppurated blood-disease associated with spleen disease rather than cancer Virchow R: an autopsy case showing giant splenomagaly and whitish blood Leuko (white) + Emia (blood) = Leukemia compound Latin 11

12 12

13 CML is a stem cell disorder Hematologic stem cells Ph Ph Ph chr. Gene rearrangements observed in CML Ph No.9 ABL gene der(9) tyrosine kinase activity(-) Ph chr. der(9) der(22) ABL/BCR gene ABL/BCR mrna (expressed in 70%) BCR/ABL gene BCR/ABL mrna tyrosine kinase activity(+++) 9q34: 22q11: No.22 BCR gene BCR/ABL protein (expressed in 100%) ABL gene BCR gene 13

14 Evidence of fusion of BCR gene and ABL gene No. 9 der( 9) der( 22) No.22 Cen ASS gene ABL gene 9q34 Intr.1 Int. 2 LSI ABL probe ( 650 kb) Tel LAMC3 gene nl(9) Cen GNAZgene BCR gene 22q11 M-BCR Tel LSI BCR probe ( 300 kb) nl(22) der(9) der(22) FISH study ABL gene BCR gene 14

15 2 types of Ph(-) CML No. 9 der( 9) No.22 der( 22) BCR/ABL fusion gene(+) The same as Ph(+)CML der( 22) No.22 der( 9) No. 9 BCR/ABL fusion gene(-) FISH, RT-PCR 15

16 der(9) deletion standard Ph trans. nl(22) nl(9) der(9) deletion It will occur when Ph trans. occurs nl(22) der(22) der(22) der(9) nl(9) der(9) the most powerful prognostic factor (tumor suppressor genes should be included in deleted region) 16

17 Typical clinical course of CML patients During CP, moderate clinical course W BC Only Ph chr. Chronic phase In 3-4 years, progress to more aggressive disease accelerated phase Acute phase Blasts +Ph +8 i(17q) Features of chronic phase Leukocytosis + basophilia hepatosplenomegaly Immature granulocytes < 5% Ph > 95%, additional chr. Abn.(-) Criteria of BC yrs myeloblasts >= 5%, promyeloblasts >= 20% additional chr. Abnormalities (+Ph,+8,iso(17q),+19,+21) lymph node enlargement, blastoma, treatment-resistant splenomegaly 17

18 Typical clinical course of CML patients During CP, moderate clinical course W BC Only Ph chr. Chronic phase +Ph In 3-4 years, progress to more aggressive disease +8 i(17q) accelerated phase Acute phase Blasts yrs +Ph +8 i(17q) Typical additional chromosome abnormalities 18

19 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin pollution in Vietnam by Kanazawa University and our direction of further study 6. Dioxin pollution in Japan: in the past and the present 19

20 Prognosis comparison of CML patients with hydroxyurea treatment Southern VN (Tuan TQ. J : Vietnam Med 2002; 5: 9-12) Northern VN (Thanh NH: in personal communication) (Hehlmann H et al., Blood 1993; 82: ) France (The Benelux CML study group. Blood 1998; 91: ) No. of patients analyzed Median survival (mo) month survival (%) Prognosis of CML patients in southern Vietnam is extremely bad. Compared with that in northern Vietnam 20

21 1. Why is the prognosis of CML patients in southern Vietnam so bad? 2. Are there specific molecular and cytogenetic features in southern Vietnamese CML patients? 3. If any, are they associated with damage of dioxin pollution during Vietnam War? Molecular and cytogenetic study of southern Vietnam CML ----Collaborated study with Blood transfusion and Hematology Hospital at Ho Chi Minh City--- 21

22 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin pollution e in Vietnam by Kanazawa University and our direction of further study 6. Dioxin pollution in Japan: in the past and the present 22

23 Materials and Methods 47 patients BM or PB 1) at diagnosis: 32 2) in chronic phase: 10 3) in accelerated phase : 5 47 FISH study Chromosome study M Patient 45 Patient 46 Patient 47 Patient 42 HT93A N K562 RT-PCR study b3a2 (287 bp) b2a2 (212 bp) ABL inner control (160 bp) 23

24 Chromosome study 1. Frequency of Ph(+) and Ph(-) CML 2. Karyotype analysis 24

25 Results of chromosome study--1 Ph(+) CML: 44/47 (93.6%) Ph (-) CML: 3/47 (6.4%) 2 types of Ph(-) CML Frequencies of Ph(-) CML China: 5.0% Canada: 5.0% India: 5.0% Japan: 0.5% Gene rearrangements in Ph(-) BCR/ABL(+) CML 50%--BCR/ABL(+) the same disease as Ph(+)CML 50%--BCR/ABL(-) a different disease from Ph(+)CML, similar to MDS/MPD? Detection by FISH, RT-PCR 25

26 Clinical and cytogenetic findings of 3 Ph(-) CML patients Pt. No Age/ Sex Phase obtained sample (mo. after diagnosis) Source WBC counts at diag. (x10 9 /L) WBC counts at sampling (x10 9 /L) Platelet counts at diag. (x10 9 /L) Monocytosis at diag. Cytogenetic finding FISH finding of BCR/ABL Major BCR/ABL mrna ABL/BCR mrna 45 40F CP (11) BM ,XX (+) Type 2 b2a2 & b3a2 (-) 46 75F CP (23) BM ,XX (-) b2a2 1b-b M Dx (0) BM ,XY (-) b3a2 1b-b4 Ph(-) no BCR/ABL FISH signals 15 metaphase 200 interphase cells BCR/ABL transcripts (+) 2 clones Major clone BCR/ABL(-) Minor clone < 1/200 (0.5%) BCR/ABL(+) 26

27 Result of chromosome study-2 a) at Dx: 4/10 (40.0%) b) in CP: 11/32 (34.4%) c) in AP: 2/ 5 (40.0%) 17/47 (36.2%) } among CP-patients 15/42 (35.7%) Completely different abnormalities from additional abnormalities such as +Ph, +8, +i(17q), +19, +21 trisomy 13 add(1)(p36) +add(1)(p31) del(3)(p21p23) add(6)(p22) del(7)(p14p15) add(10)(p13) add(11)(p15) Xinh PT, et al. Cancer Genet Cytogenet 168:59-68,

28 Southern Vietnam Other countries In chronic phase: 15/42 (35.7%) In chronic phase: % (Anastasi et al., Leukemia, 1995;9: ) In blastic phase: about 80% double Ph, +8, iso(17q), +19 and +21 (Kantarjian et al., Blood, 1993;82: ) Among CML patients in southern Vietnam, previously unreported chromosome abnormalities were found in chronic phase with high frequency 28

29 FISH study 1. Analysis of BCR/ABL breakpoints 2. The frequency of der(9) deletion 29

30 In the same patient, cells with standard Ph translocation and cells with der(9) deletion were found. der(9) deletion A B nl(9) der(9) C der(9) standard Ph transl. nl(9) der(22) der(22) nl(22) nl(22) Xinh PT, et al. Cancer TGenet Cytogenet 164: , T

31 There are 2 clones Pt. 3 Pt. 5 1) Cells with standard Ph translocation ) Cells with der(9) deletion 3 4 der(9) deletion Ph translocation clones der(9) deletion The first report which showed that der(9) deletion occurs in the progression of disease. (Xinh PT, et al. Cancer Genet Cytogenet 164: ,

32 Summary 1. Unique chromosomal abnormalities were found with high frequency at diagnosis: 4/10 (40.0%) in chronic phase: 11/32 (34.4%) 2. der(9) deletion was found with high frequency: 11/47(23.4%) 3. 2 kinds of clones in the same patient: 1) a clone with der(9) deletion and one without it 2) a clone with BCR/ABL gene and one without it Is there the existence of genomic instability? 32

33 What is the cause of inducing genomic instability? Influences of dioxins pollution 33

34 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxins pollution in Vietnam by Kanazawa University and our direction of further study 6. Dioxins pollution in Japan: in the past and the present 34

35 Long term effects of war agent orange/dioxins on human health of people who have lived in a sprayed area Selected about 4100 individuals from 2 areas with similar life style on both sides of Lat. 17 N non-sprayed area (Cam Phuc commune northern VN) heavily sprayed area (Cam Chinh commune southern VN Lat. 17 N A large scaled endemic study (stillbirth, congenital abnormalities, birth rate of boy and girl, nutrition condition) Measurement of dioxins in the environment soil, water, domestic fowl and pig) Measurement of dioxins in human tissues (serum, adipose tissue, and breast milk) from individuals Even now (30 years after Vietnam War), individuals in a heavily sprayed area showed 3-4 times higher level of serum dioxin compared with individuals in a non-sprayed area. However, some individuals showed low dioxins level. 35

36 Measurement of dioxins by Prof. Teruhiko Kido (Kanazawa University and Kanazawa Medical University) Using 5 ml serum or 10 ml breast milk, 6 kinds of dioxins are measurable Highest detection level in the world 36

37 Next Plan High dioxin group Low dioxin group Sprayed area 3 Control Non-sprayed area Sister chromatid exchange 1. Chromosome analysis of T cells 2. Sister chromatid exchange (SCE) analysis 3. P450(CYP2D6) analysis 37

38 Next Plan-2 1. Among people with high dioxins value: Do they show chromosomal abnormalities? Do they show high SCE index? 2. Among people with low dioxins value: Do they show specific P450 subtype? 38

39 Today s Talk 1. Dioxin and defoliant pollution caused by Vietnam War 2. What is chronic myeloid leukemia (CML)? 3. What prompted us to start this research? 4. Unique features of chronic myeloid leukemia in southern Vietnam 5. Epidemiologic study of dioxin pollution in Vietnam by Kanazawa University and our direction of further study 6. Dioxins pollution in Japan: in the past and the present 39

40 Dioxin pollution in Japan Damages by defoliants used during the Vietnam War make an issue Dioxins were detected in ash of incinerators 74% of garbage were burned in incinerators 2000 incinerators in the whole country produce 17kg dioxin a year, which is 1/10 of a total amount of dioxins used in Vietnam War. A total amount of agricultural chemicals used for 30 years since 1960s is equal to a total amount of dioxins used in the Vietnam War Guideline for prevention of dioxin generation Designate dioxin as a substance for Law of Prevention for Air Pollution Principle guideline for measures against dioxin Goal: within 4 years, 90% reduction compared with the value of

41 Dioxin pollution in Japan--2 Change of dioxins discharge from incinerators - 98% : special law of measurement against dioxins : come into force of the law : complete enforcement 2003 year discharge decreased to 145 g industrial about 74 g, domestic about 71 g) Problems to be solved in the future 1. Measure dioxin discharge from small incinerators 2. Close and improve inappropriate final treatment of industrial waste 3. Scrap incinerators smoothly 41

42 Changes of dixions discharge and dixions level in air and water in Japan borrowed from Prof. Kido, Kanazawa Univ

43 Change of daily intake of dioxins borrowed from Prof. Kido, Kanazawa Univ. 43

44 Change of dioxins level in human breast milk borrowed from Prof. Kido, Kanazawa Univ. Still higher than that of control group in southern Vietnam borrowed from Prof. Kido, Kanazawa Univ. 44

45 Daily intake of dioxins/person in Japan WHO TDI borrowed from Prof. Kido, Kanazawa Univ. TEQ: toxicity equivalecy quantity TEF: toxic equivalecy factor 45

46 Thank you for your attention 46

Role of FISH in Hematological Cancers

Role of FISH in Hematological Cancers Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk

More information

Hormonally active contaminants- Interactions and effects on food safety. Helen Håkansson

Hormonally active contaminants- Interactions and effects on food safety. Helen Håkansson Hormonally active contaminants- Interactions and effects on food safety Contents EDC definition and effects Effects of dioxin-like compounds TEQ concept and TEF values for dioxin-like compound Need of

More information

Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML

Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae

More information

Hematopathology Case Study

Hematopathology Case Study Hematopathology Case Study AMP Outreach Course 2009 AMP Annual Meeting John Greg Howe Ph.D. Department of Laboratory Medicine Yale University School of Medicine November 19, 2009 HISTORY Case History An

More information

Persistent Organic Pollutants (POPs) in Human Breast Milk Collected from Asian Developing Countries: Risk Assessment for Infants

Persistent Organic Pollutants (POPs) in Human Breast Milk Collected from Asian Developing Countries: Risk Assessment for Infants Persistent Organic Pollutants (POPs) in Human Breast Milk Collected from Asian Developing Countries: Risk Assessment for Infants Shinsuke Tanabe Ehime University, Japan SL 1: Title Thank you Mr. Chairman

More information

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Myeloproliferative Disorders - D Savage - 9 Jan 2002 Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2

More information

TISSUE SCREENING LEVEL GUIDELINES FOR ISSUANCE OF PUBLIC HEALTH ADVISORIES FOR SELECTED CONTAMINANTS and Supporting Documentation

TISSUE SCREENING LEVEL GUIDELINES FOR ISSUANCE OF PUBLIC HEALTH ADVISORIES FOR SELECTED CONTAMINANTS and Supporting Documentation March 2012 TISSUE SCREENING LEVEL GUIDELINES FOR ISSUANCE OF PUBLIC HEALTH ADVISORIES FOR SELECTED CONTAMINANTS and Supporting Documentation Louisiana Department of Environmental Quality Louisiana Department

More information

Media centre. Dioxins and their effects on human health. Key Facts. 1 of 7 1/7/11 1:31 PM

Media centre. Dioxins and their effects on human health. Key Facts. 1 of 7 1/7/11 1:31 PM Media centre Dioxins and their effects on human health Fact sheet N 225 May 2010 Key Facts Dioxins are a group of chemically-related compounds that are persistent environmental pollutants. Dioxins are

More information

Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute

Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase

More information

National Chemical Contaminants Programme

National Chemical Contaminants Programme National Chemical Contaminants Programme Dairy Products and Raw Milk Dioxin, Dioxin-like PCB, and Indicator PCB Results (2014, 2015, and 2016) MPI Technical Paper No: 2017/25 By MPI Regulation and Assurance

More information

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte

More information

Certificate of Analysis

Certificate of Analysis 5420 Mainway Drive, Unit 5, Burlington ON, L7L 6A4 Phone: 905-33-3, FAX: 905-33-4567 Certificate of Analysis ALS Project Contact: Steve Kennedy Client Name: ISKY Chemicals Co Ltd ALS Project ID: SKY300

More information

(Non-legislative acts) REGULATIONS

(Non-legislative acts) REGULATIONS 29.3.2012 Official Journal of the European Union L 91/1 II (Non-legislative acts) REGULATIONS COMMISSION REGULATION (EU) No 277/2012 of 28 March 2012 amending Annexes I and II to Directive 2002/32/EC of

More information

Arkansas Department of Health

Arkansas Department of Health Mr. Jim Wise Ecologist Coordinator, Office of Water Arkansas Department of Environmental Quality 5301 Northshore Drive North Little Rock, AR 72118-5317 Dear Mr. Wise: Arkansas Department of Health 4815

More information

Hematopathology Case Study

Hematopathology Case Study www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated

More information

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. 1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)

More information

DETERMINATION OF DIOXINS AND DIOXIN-LIKE PCBs IN FOOD PRODUCTS IN ACCORDANCE WITH NORMS OF EUROPEAN COMMUNITY

DETERMINATION OF DIOXINS AND DIOXIN-LIKE PCBs IN FOOD PRODUCTS IN ACCORDANCE WITH NORMS OF EUROPEAN COMMUNITY DETERMINATION OF DIOXINS AND DIOXIN-LIKE PCBs IN FOOD PRODUCTS IN ACCORDANCE WITH NORMS OF EUROPEAN COMMUNITY V.Chmil Medved s Institute of Ecohygiene and Toxicology, Kiev, Ukraine, E-mail: cvd@medved.kiev.ua

More information

Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia

Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia Pak J Med Res Vol. 57, No. 4, 2018 Original Article Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia Khadija Iftikhar, Chaudhry Altaf Hussain,

More information

CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML

CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

COMMISSION REGULATION (EU)

COMMISSION REGULATION (EU) L 320/18 Official Journal of the European Union 3.12.2011 COMMISSION REGULATION (EU) No 1259/2011 of 2 December 2011 amending Regulation (EC) No 1881/2006 as regards maximum levels for dioxins, dioxin-like

More information

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features

More information

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22) PML/RARA t(15;17) Translocation Assay Result : nuc ish(pml 2)(RARA 2)[200] : 200/200(100%) interphase nuclei show normal 2O 2G signals for PML/RARA : is Negative for t(15;17)(q22;q21.1) 2 Orange 2 Green

More information

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP

Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS

More information

Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015

Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015 Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions

More information

Dioxins in Vietnamese, Vietnamese Food and Environment: Potential Relevance of Hot Spots from Recent Findings

Dioxins in Vietnamese, Vietnamese Food and Environment: Potential Relevance of Hot Spots from Recent Findings Dioxins in Vietnamese, Vietnamese Food and Environment: Potential Relevance of Hot Spots from Recent Findings Olaf Päpke and Arnold Schecter eurofins - ERGO Research, Hamburg, Germany University of Texas,

More information

Chronic myeloid leukemia (CML)

Chronic myeloid leukemia (CML) Bioscientia Int. Support Services Dept. Konrad-Adenauer-Strasse 17 55218 Ingelheim Germany Phone 49(0)6132-781-203 49(0)6132-781-224 49(0)6132-781-165 Fax 49(0)6132-781-236 int.support@bioscientia.com

More information

MRD in CML (BCR-ABL1)

MRD in CML (BCR-ABL1) MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:

More information

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms

Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)

More information

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and

Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type

More information

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013 Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie

More information

Dioxins in the food chain: An endless story?

Dioxins in the food chain: An endless story? Scientific Committee of the Federal Agency for the Safety of the Food Chain Dioxins in the food chain: An endless story? L. Pussemier, V. Vromman and C. Saegerman Workshop on Risk assessment and food safety,

More information

The State of Dioxin Accumulation in the Human Body, Blood, Wildlife, and Food:

The State of Dioxin Accumulation in the Human Body, Blood, Wildlife, and Food: The State of Dioxin Accumulation in the Human Body, Blood, Wildlife, and Food: Findings of the Fiscal 1998 Survey December 27, 1999 (Monday) Environmental Health and Safety Division, Environmental Health

More information

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data

Form 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)

More information

ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA

ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA 1Rosline H, 1Majdan R, 1Wan Zaidah A, 1Rapiaah M, 1Selamah G, 2A A Baba, 3D M Donald 1Department of Haematology, 2Department

More information

Dow Epidemiology Studies Among Workers with Exposure to Dioxins and Dioxin-like Compounds

Dow Epidemiology Studies Among Workers with Exposure to Dioxins and Dioxin-like Compounds 1 Dow Epidemiology Studies Among Workers with Exposure to Dioxins and Dioxin-like Compounds James J. Collins, PhD, MS Catherine M. Bodnar,, MD, MPH Outline Chemistry Toxicology Sources of Exposure http://www.epa.gov/osw/nonhaz/munici

More information

Between 1962 and 1971, Agent Orange

Between 1962 and 1971, Agent Orange JOEM Volume 43, Number 5, May 2001 435 Recent Dioxin Contamination From Agent Orange in Residents of a Southern Vietnam City Arnold Schecter, MD, MPH Le Cao Dai, MD Olaf Päpke, MS Joelle Prange, MS John

More information

Chronic Idiopathic Myelofibrosis (CIMF)

Chronic Idiopathic Myelofibrosis (CIMF) Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation

More information

Prepared by: Dr.Mansour Al-Yazji

Prepared by: Dr.Mansour Al-Yazji C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form

More information

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009 LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome 3.3 X 10 9 DNA basepairs Estimated genetic constitution 30,000

More information

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Significance of Chromosome Changes in Hematological Disorders and Solid Tumors Size of Components of Human Genome Size of haploid genome! Estimated genetic constitution! Size of average chromosome

More information

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia

More information

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib

screening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis

More information

L 32/44 Official Journal of the European Union

L 32/44 Official Journal of the European Union L 32/44 Official Journal of the European Union 4.2.2006 COMMISSION DIRECTIVE 2006/13/EC of 3 February 2006 amending Annexes I and II to Directive 2002/32/EC of the European Parliament and of the Council

More information

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC

Molecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing

More information

Mixed Phenotype Acute Leukemias

Mixed Phenotype Acute Leukemias Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based

More information

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew

More information

CML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL

CML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL 1 Key Wordschronic myeloid leukemiaimatinib mesylate tyrosine kinase inhibitor chronic myeloid leukemia CML imatinib mesylate CML CML CML CML Ph 10 1 30 50 3 5 CML α IFNα Ph Ph cytogenetic response CRmajor

More information

Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body

Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,

More information

Managing Chronic Myeloid Leukemia

Managing Chronic Myeloid Leukemia Concise Reference Managing Chronic Myeloid Leukemia Timothy P Hughes, David M Ross, Junia V Melo Extracted from Handbook of Chronic Myeloid Leukemia Published by Springer Healthcare Ltd, 236 Gray s Inn

More information

Available online at

Available online at Available online at www.ehs.or.kr Relative Potency Estimation of Dioxin-like Activity by Dioxins, Furans, and Co-planar PCBs Using Chemically Activated Luciferase Gene Expression Assay (H4IIE-luc Assay)

More information

Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3

Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3 American Journal of Hematology 74:268 272 (2003) Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3 Li-Gen Liu, 1,2 Hideo Tanaka,

More information

Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients

Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients ORIGINAL ALBANIAN MEDICAL RESEARCH JOURNAL Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients Dorina Roko 1, Anila Babameto-Laku

More information

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16 35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will

More information

Case Presentation. Attilio Orazi, MD

Case Presentation. Attilio Orazi, MD Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia

More information

Juvenile Myelomonocytic Leukemia Pre-HCT Data

Juvenile Myelomonocytic Leukemia Pre-HCT Data Instructions for Juvenile Myelomonocytic Leukemia Pre-HCT Data (Form 2015) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the JMML Pre-HCT Form. E-mail

More information

Heme 9 Myeloid neoplasms

Heme 9 Myeloid neoplasms Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia

More information

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We

More information

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University

More information

-19. -Mousa Salah. -Shahd Alqudah. -Dr Belal

-19. -Mousa Salah. -Shahd Alqudah. -Dr Belal التزام -19 -Mousa Salah -Shahd Alqudah -Dr Belal 1 P a g e In the previous lecture we talked about the numerical chromosomal abnormalities, they are either autosomal or sex, and we said that the chromosomal

More information

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+) Version: CMLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is

More information

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Case Study Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation Ling Wang 1 and Xiangdong Xu 1,2,* 1 Department of Pathology, University of California, San Diego; 2

More information

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose. RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May

More information

Flow Cytometry. Leukemia and Myelodysplastic Syndromes. Bone Marrow Aspirate and Biopsy

Flow Cytometry. Leukemia and Myelodysplastic Syndromes. Bone Marrow Aspirate and Biopsy Diagnostic Evaluation of Blood Disorders Leukemia and Myelodysplastic Syndromes Lenise Taylor, MN, RN, AOCNS, BMTCN BMT/Immunotherapy CNS Seattle Cancer Care Alliance/UWMC ltaylor@seattlecca.org History

More information

Title. CitationAnnals of Hematology, 82(9): Issue Date Doc URL. Rights. Type. File Information. major BCR/ABL

Title. CitationAnnals of Hematology, 82(9): Issue Date Doc URL. Rights. Type. File Information. major BCR/ABL Title A case of myelodysplastic syndrome developed blastic major BCR/ABL Author(s)Onozawa, Masahiro; Fukuhara, Takashi; Takahata, Muts CitationAnnals of Hematology, 82(9): 593-595 Issue Date 2003-09 Doc

More information

Study of POPs Levels in the Breast Milk of Women - Residents of Chelyabinsk Oblast (Karabash) and Tyumen Oblast (Tobolsk)

Study of POPs Levels in the Breast Milk of Women - Residents of Chelyabinsk Oblast (Karabash) and Tyumen Oblast (Tobolsk) International POPs Elimination Project Fostering Active and Efficient Civil Society Participation in Preparation for Implementation of the Stockholm Convention Study of POPs Levels in the Breast Milk of

More information

Acute myeloid leukemia. M. Kaźmierczak 2016

Acute myeloid leukemia. M. Kaźmierczak 2016 Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production

More information

CML MANAGEMENT IN EMERGING COUNTRIES: ACCESS TO MONITORING

CML MANAGEMENT IN EMERGING COUNTRIES: ACCESS TO MONITORING CML MANAGEMENT IN EMERGING COUNTRIES: ACCESS TO MONITORING N. A. O T H I E N O - A B I N Y A U N I V E R S I T Y O F N A I R O B I, N A I R O B I - K E N Y A KENYA COUNTRY PROFILE Location Total population

More information

CML TREATMENT GUIDELINES

CML TREATMENT GUIDELINES CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,

More information

Case Report Synchronous Occurrence of Chronic Myeloid Leukemia and Mantle Cell Lymphoma

Case Report Synchronous Occurrence of Chronic Myeloid Leukemia and Mantle Cell Lymphoma Hindawi Case Reports in Hematology Volume 2017, Article ID 7815095, 4 pages https://doi.org/10.1155/2017/7815095 Case Report Synchronous Occurrence of Chronic Myeloid Leukemia and Mantle Cell Lymphoma

More information

Venice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann

Venice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help

More information

Dioxins and PCBs in Food

Dioxins and PCBs in Food ISSUE NO. 1 MAY 2009 The aim of this document is to provide food business operators (FBOs), enforcement officers and other stakeholders with a concise overview of the health hazards of, and sources of

More information

If unqualified, Complete remission is considered to be Haematological complete remission

If unqualified, Complete remission is considered to be Haematological complete remission Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous

More information

Blast Phase Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast

More information

RESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.

RESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,

More information

Session 5 Children s Health

Session 5 Children s Health 2002 Session 5 Children s Health Regional Differences and Temporal Trends in Semen Quality Niels Jørgensen Rigshospitalet, Denmark Recent retrospective studies on secular trends in male reproductive health

More information

If unqualified, Complete remission is considered to be Haematological complete remission

If unqualified, Complete remission is considered to be Haematological complete remission Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous

More information

A pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH

A pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir

More information

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Extramedullary precursor T-lymphoblastic transformation of CML at presentation Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency

More information

Questions and Answers on Dioxins and PCBs

Questions and Answers on Dioxins and PCBs MEMO/06/54 Brussels, 03 February 2006 Questions and Answers on Dioxins and PCBs What are dioxins? Dioxins are a group of chemicals. They are polychlorinated aromatic compounds with similar structures,

More information

C Longer follow up on IRIS data

C Longer follow up on IRIS data hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring

More information

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

Diagnosis. Chapter 2. Diagnostic laboratory tests. Blood picture and biochemistry. Bone marrow morphology

Diagnosis. Chapter 2. Diagnostic laboratory tests. Blood picture and biochemistry. Bone marrow morphology Chapter 2 Diagnosis When a patient presents with suspected chronic myeloid leukemia (CML) appropriate assessments are needed to confirm the diagnosis and stage of disease, and to assign a risk score to

More information

( Compauson of the JJsefulness_and_CoSts of R.r.AhI Analysis yprcnc. Chromosome Analyse

( Compauson of the JJsefulness_and_CoSts of R.r.AhI Analysis yprcnc. Chromosome Analyse GARY MOCKLI ( Compauson of the JJsefulness_and_CoSts of R.r.AhI Analysis yprcnc Chromosome Analyse S^cv"to^n^termine Wh6ther bcr'abi anai>'sis can be utilized to ^valua* 7hSf I?f.Cemin hematopoietic malignancies

More information

Juvenile Myelomonocytic Leukemia (JMML)

Juvenile Myelomonocytic Leukemia (JMML) Juvenile Myelomonocytic Leukemia (JMML) JMML: Definition Monoclonal hematopoietic disorder of childhood characterized by proliferation of the granulocytic and monocytic lineages Erythroid and megakaryocytic

More information

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome

More information

Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML

Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML reprinted from november 2014 pathology laboratory medicine laboratory management Molecular techniques in a case of concurrent BCR-ABL1 positive CML and CMML CAP TODAY and the Association for Molecular

More information

Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012

Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically

More information

Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE

Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE If searched for the ebook by DEISSEROTH Chronic Myelogenous Leukemia (Hematology) in pdf format, in that case you come on to correct

More information

CML and Future Perspective. Hani Al-Hashmi, MD

CML and Future Perspective. Hani Al-Hashmi, MD CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All

More information

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic

More information

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010 Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)

More information

MP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

MP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia

More information

Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia

Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia Kamla-Raj 2003 Int J Hum Genet, 3(2): 115-119 (2003) Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia Prochi Madon, Arundhati Athalye, Vijay

More information

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

How I treat high risck CML

How I treat high risck CML Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:

More information

Original Article. Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients

Original Article. Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients Original Article Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients Ali M.Jawad * CABM FRCP (Edin) Batool A.G. Yassin** FICM.CM Nabeel Salman*** FRCP (Edin) Ali Al-Ameri**** CABM

More information